Table 2.
Summary of used cidofovir and reported dysplasia in reviewed studies
| Reference | No. of patients | Cidofovir (mean value, range in parentheses) | Dysplasia | |||||
|---|---|---|---|---|---|---|---|---|
| No. of injections | Concentration (mg/ml) | Cumulative dose (mg) | Injection interval | Therapy period (months) | Follow-up period (months) | |||
| Pudszuhn et al. and Neumann et al.a [39, 48] | 10 | 4.3 (2–7) | 5 | 33.8 (9–80) | 4 weeks | N/A (2–15) | 19 (8–30) | 1 patient |
| Naiman et al. and Coulombeau et al.a [14, 36, 37] | 16 | 9 (2–26) | 5–7.5 | N/A | 2–4 weeks | 24 (1–68) | 33.6 (12–76) | None |
| Naiman et al. and Coulombeau et al.a [14, 35, 37] | 19 | 4.5 (1–11) | 5–7.5 | N/A | 2–4 weeks | N/A (1–47) | 24 (8–57) | |
| Chung et al. and Akst et al.a, b [1, 12] | 6 | 4 (N/A) | 5 | 22.4 (7–42.5) | 1 month | 4 (N/A) | 30.2 (10–45) | None |
| 5 | 8 (N/A) | 5–10 | 73.8 (52–107) | 1 month | 8 (N/A) | |||
| Sheahan et al. [50] | 4 | 10.5 (8–18) | 5 | 204.8 (N/A) | 3–5 weeks | 10.5 (7–16) | N/A | None |
| Pontes et al. [43] | 10 | 4.2 (2–8) | 6 | 75.6 (36–144) | N/A | N/A (6–24) | N/A | None |
| Dikkers [20] | 9 | 9 (6–17) | 2.5 | 64 (10.5–128) | 6 weeks | N/A | 20 (6–36) | 1 patient |
| Wemer et al. [55] | 1 | N/A | 5 | N/A | N/A | 27 | N/A | 1 patient |
| Palomar et al. [40] | 1 | 1 | 2.5 | N/A | N.V.T. | <1 | 12 | None |
| de Bilderling et al. [18] | 1 | 32 | N/A | N/A | 1.5 months | 31 | 24 | None |
| Askew et al. [3] | 4 | 7 (2–15) | 5 | N/A | N/A | N/A | N/A | None |
| Lee et al. [30] | 16 | 3.5 (1–9) | 2.5–5 | 129 (25–360) | 3 weeks | N/A | 25.4 (13–48) | None |
| Co et al. [13] | 5 | 4.4 (3–7) | 7.5 | 75 (45–112.5) | 1 month | 3.5 (2–6) | 6.5 (2–10) | None |
| Mandell et al. [32] | 4 | 4 (2–7) | 5 | N/A | 2 months | 10 (4–18) | 26.5 (20–30) | None |
| Peyton et al. [42] | 11 | 6 (4–16) | 5 | N/A | 2 weeks | N/A | 30 (N/A) | None |
| Avelino et al. [4] | 5 | 8 (5–10) | 7.5 | N/A | 2–3 weeks | N/A | 14 (12–16) | None |
| Chhetri et al. [11] | 5 | 13 (8–22) | 5 | N/A | 2 weeks | 15 (8–29) | 15 (N/A) | None |
| Milczuk [33] | 4 | 6 (6–7) | 5 | 52 (46–63) | 6–8 weeks | 9.5 (8–13) | 14 (12–16) | None |
| Pransky et al.a [45–47] | 11 | 9 (4–28) | 2.5–5 | N/A | 2–4 weeks | 9 (2–51) | 43 (9–65) | None |
| El Hakim et al. [22] | 2 | 3 | 5 | N/A | 2 weeks | 1 | 12 | None |
| Bielamowicz et al. [6] | 13 | 6 (1–19) | 4.17–6.25 | 140 (N/A) | 1 months | 12 (1–44) | N/A | None |
| Chhetri et al. [9] | 5 | 7 (2–12) | 37.5 | 348 (N/A) | 2–4 weeks | 12 (7–16) | 12 (7–16) | None |
| El Aatmani et al. [21] | 1 | 2 | 15 | N/A | 3 months | 3 | N/A | None |
| Wilson et al. [56] | 3 | N/A | 4.17 | N/A (21–42) | 2–4 weeks | N/A | 24 | None |
| Snoeck et al. [51] | 17 | 7 (2–15) | 2.5 | 116 (30–259) | 2–4 weeks | 5 (1–13) | 15 (2–27) | 2 patients |
| Total | 188 | 5 | ||||||
aOverlap in patient population
bData split because of two different treatment protocols